This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig 2CV v3.1 was used to generate the results found in this report.
-
Working with individual set: LIHC-TP
-
Number of patients in set: 198
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:LIHC-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 13
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
nnon = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | longname | codelen | nnei | nncd | nsil | nmis | nstp | nspl | nind | nnon | npat | nsite | pCV | pCL | pFN | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | TP53 | tumor protein p53 | 1314 | 25 | 0 | 1 | 41 | 8 | 5 | 9 | 63 | 62 | 50 | 1e-16 | 0.0012 | 0.00021 | 1e-16 | 9.1e-13 |
2 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 2406 | 42 | 0 | 2 | 50 | 0 | 0 | 4 | 54 | 51 | 26 | 1e-16 | 1e-05 | 0.099 | 1e-16 | 9.1e-13 |
3 | RB1 | retinoblastoma 1 (including osteosarcoma) | 2891 | 80 | 0 | 1 | 3 | 1 | 3 | 10 | 17 | 15 | 17 | 1.3e-15 | 1 | 0.76 | 4.5e-14 | 2.8e-10 |
4 | AXIN1 | axin 1 | 2629 | 160 | 0 | 1 | 1 | 0 | 3 | 6 | 10 | 9 | 10 | 5.6e-09 | 1 | 0.2 | 4.9e-08 | 0.00022 |
5 | BAP1 | BRCA1 associated protein-1 (ubiquitin carboxy-terminal hydrolase) | 2254 | 5 | 0 | 0 | 3 | 2 | 1 | 4 | 10 | 10 | 10 | 1.2e-07 | 0.13 | 0.15 | 8.7e-08 | 0.00032 |
6 | TSC2 | tuberous sclerosis 2 | 5590 | 16 | 0 | 1 | 2 | 2 | 0 | 5 | 9 | 9 | 9 | 1.2e-07 | 1 | 0.02 | 1.9e-07 | 0.00057 |
7 | ARID1A | AT rich interactive domain 1A (SWI-like) | 6934 | 0 | 0 | 1 | 5 | 4 | 1 | 7 | 17 | 16 | 16 | 2.2e-07 | 0.12 | 0.64 | 6.1e-07 | 0.0016 |
8 | IL6ST | interleukin 6 signal transducer (gp130, oncostatin M receptor) | 2817 | 11 | 0 | 1 | 1 | 1 | 0 | 5 | 7 | 7 | 7 | 6.5e-08 | 1 | 0.64 | 1.1e-06 | 0.0026 |
9 | ALB | albumin | 1888 | 2 | 0 | 2 | 8 | 0 | 2 | 11 | 21 | 18 | 20 | 3.2e-07 | 0.3 | 0.48 | 1.4e-06 | 0.0028 |
10 | HNF1A | HNF1 homeobox A | 1934 | 58 | 0 | 0 | 8 | 1 | 1 | 2 | 12 | 8 | 12 | 7.2e-07 | 1 | 0.73 | 0.000011 | 0.019 |
11 | APOB | apolipoprotein B (including Ag(x) antigen) | 13804 | 19 | 0 | 3 | 16 | 2 | 0 | 8 | 26 | 24 | 26 | 7.6e-06 | 1 | 0.046 | 0.000011 | 0.019 |
12 | EEF1A1 | eukaryotic translation elongation factor 1 alpha 1 | 1417 | 111 | 0 | 0 | 6 | 0 | 0 | 0 | 6 | 5 | 3 | 0.0028 | 0.0011 | 0.3 | 0.000047 | 0.072 |
13 | KIF19 | kinesin family member 19 | 3073 | 24 | 0 | 0 | 9 | 0 | 0 | 1 | 10 | 10 | 10 | 8.5e-06 | 1 | 0.47 | 0.000064 | 0.089 |
14 | GNAS | GNAS complex locus | 4050 | 40 | 0 | 0 | 7 | 0 | 0 | 0 | 7 | 7 | 5 | 0.0037 | 0.0012 | 0.9 | 0.000087 | 0.11 |
15 | F5 | coagulation factor V (proaccelerin, labile factor) | 6771 | 2 | 0 | 0 | 3 | 0 | 1 | 0 | 4 | 4 | 3 | 0.1 | 0.0018 | 0.0073 | 0.00013 | 0.15 |
16 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 1244 | 412 | 0 | 0 | 2 | 1 | 1 | 3 | 7 | 7 | 7 | 0.000012 | 1 | 0.78 | 0.00015 | 0.17 |
17 | HIST1H1C | histone cluster 1, H1c | 646 | 374 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 5 | 0.00035 | 0.036 | 0.88 | 0.00019 | 0.2 |
18 | DLK2 | delta-like 2 homolog (Drosophila) | 1172 | 31 | 0 | 0 | 3 | 0 | 0 | 1 | 4 | 4 | 4 | 0.000032 | 1 | 0.56 | 0.00036 | 0.36 |
19 | THADA | thyroid adenoma associated | 6010 | 16 | 0 | 0 | 3 | 2 | 0 | 1 | 6 | 6 | 6 | 0.000054 | 1 | 0.65 | 0.00058 | 0.56 |
20 | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 503 | 172 | 0 | 0 | 4 | 0 | 0 | 1 | 5 | 4 | 5 | 0.00084 | 1 | 0.034 | 0.00066 | 0.6 |
21 | IDH1 | isocitrate dehydrogenase 1 (NADP+), soluble | 1277 | 482 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 1 | 0.074 | 0.001 | 0.69 | 0.00077 | 0.67 |
22 | PRKDC | protein kinase, DNA-activated, catalytic polypeptide | 12728 | 12 | 0 | 2 | 9 | 1 | 2 | 0 | 12 | 12 | 11 | 0.0022 | 0.03 | 0.57 | 0.00085 | 0.7 |
23 | GRM8 | glutamate receptor, metabotropic 8 | 2815 | 7 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 4 | 4 | 0.85 | 6e-05 | 0.51 | 0.001 | 0.83 |
24 | HGS | hepatocyte growth factor-regulated tyrosine kinase substrate | 2420 | 2 | 0 | 0 | 2 | 1 | 0 | 1 | 4 | 3 | 4 | 0.006 | 0.015 | 0.66 | 0.0011 | 0.87 |
25 | GAS2L1 | growth arrest-specific 2 like 1 | 2069 | 59 | 0 | 0 | 2 | 0 | 1 | 0 | 3 | 2 | 3 | 0.038 | 0.011 | 0.04 | 0.0013 | 0.96 |
26 | MLL2 | myeloid/lymphoid or mixed-lineage leukemia 2 | 16826 | 9 | 0 | 2 | 6 | 0 | 1 | 4 | 11 | 11 | 11 | 0.00046 | 1 | 0.26 | 0.0014 | 0.99 |
27 | KEAP1 | kelch-like ECH-associated protein 1 | 1895 | 10 | 0 | 0 | 7 | 0 | 0 | 1 | 8 | 7 | 8 | 0.00063 | 1 | 0.18 | 0.0016 | 0.99 |
28 | OAS2 | 2'-5'-oligoadenylate synthetase 2, 69/71kDa | 2282 | 162 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 5 | 0.009 | 0.015 | 0.78 | 0.0016 | 0.99 |
29 | MFSD3 | major facilitator superfamily domain containing 3 | 1257 | 157 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 2 | 2 | 0.017 | 1 | 0.01 | 0.0016 | 0.99 |
30 | RXRA | retinoid X receptor, alpha | 1425 | 115 | 0 | 0 | 5 | 0 | 0 | 0 | 5 | 5 | 5 | 0.0017 | 1 | 0.068 | 0.0016 | 0.99 |
31 | RNF145 | ring finger protein 145 | 2118 | 102 | 0 | 0 | 2 | 1 | 0 | 0 | 3 | 2 | 3 | 0.095 | 0.0019 | 0.68 | 0.0017 | 1 |
32 | ZCCHC2 | zinc finger, CCHC domain containing 2 | 3589 | 123 | 0 | 1 | 3 | 1 | 0 | 0 | 4 | 4 | 4 | 0.027 | 1 | 0.0008 | 0.0019 | 1 |
33 | SPAG6 | sperm associated antigen 6 | 1570 | 0 | 0 | 0 | 2 | 0 | 0 | 2 | 4 | 4 | 4 | 0.00024 | 1 | 0.98 | 0.0022 | 1 |
34 | SENP2 | SUMO1/sentrin/SMT3 specific peptidase 2 | 1834 | 74 | 0 | 0 | 3 | 0 | 0 | 1 | 4 | 4 | 4 | 0.012 | 0.016 | 0.62 | 0.0023 | 1 |
35 | TNFRSF4 | tumor necrosis factor receptor superfamily, member 4 | 860 | 177 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | 3 | 3 | 0.013 | 1 | 0.0087 | 0.0029 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.